Pilatus Biosciences to Present New Colorectal Cancer Data

Got story updates? Submit your updates here. ›

Pilatus Biosciences, a biopharmaceutical company, will present new data at the AACR 2026 conference highlighting the sex-specific efficacy of their CD36-targeting antibody in the treatment of colorectal cancer. The data is expected to provide insights into potential gender differences in the effectiveness of this novel cancer therapy.

Why it matters

Colorectal cancer is one of the most common and deadly forms of cancer, and new treatment approaches that can improve outcomes are critically needed. Understanding how a patient's biological sex may impact the efficacy of cancer therapies is an important area of research that could lead to more personalized and effective treatment strategies.

The details

Pilatus Biosciences has developed a CD36-targeting antibody as a potential new therapy for colorectal cancer. CD36 is a cell surface receptor that plays a role in tumor growth and metastasis. The company's new data is expected to reveal differences in how the antibody performs in male versus female patients with colorectal cancer.

• The data will be presented at the AACR 2026 conference, which is scheduled for April 12-16, 2026.

What’s next

The findings from this study could inform the design of future clinical trials to further evaluate the sex-specific efficacy of Pilatus Biosciences' CD36-targeting antibody in colorectal cancer.